This is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled
(glibenclamide) study of tesaglitazar in patients with type 2 diabetes, not adequately
controlled on diet and lifestyle advice alone during the run-in period. The study comprises a
6 week placebo single blind run in period followed by a 52-week double blind treatment period
and a 3-week follow-up period. Tesaglitazar and glibenclamide will be titrated to optimal
effect or highest tolerable dose during the first 12 weeks.